Trogarzo
Ibalizumab · Theratechnologies Inc.
CANCER MEDICINE · PRESCRIPTION ONLY (USA)Trogarzo ingredients
| Active ingredient | Strength |
|---|---|
| Ibalizumab | 150 mg/mL |
What Trogarzo is used for
Trogarzo is a cancer medicine (cd4-directed blocking antibody, human immunodeficiency virus 1 post-attachment fusion inhibitor). Its approved uses are listed on the official FDA label below.
Key facts
- Brand
- Trogarzo
- Generic name
- Ibalizumab
- Made by
- Theratechnologies Inc.
- Forms
- Injection, Solution
- Given
- Intravenous
- Drug class
- CD4-directed Blocking Antibody, Human Immunodeficiency Virus 1 Post-attachment Fusion Inhibitor
- FDA approval
- Biologic licence (BLA) BLA761065
- On the US market since
- 2018
Official information
- Trogarzo prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Ibalizumab)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Trogarzo?
Trogarzo (Ibalizumab) is a cancer medicine made by Theratechnologies Inc., approved by the US FDA.
What are the ingredients of Trogarzo?
Trogarzo contains Ibalizumab (150 mg/mL).
From the FDA National Drug Code directory (open.fda.gov, public domain). Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA